Assessment and significance of quality of life in women with gynecologic cancer

In the design of randomized clinical trials, quality of life (QOL) has become an important component across multiple cancer types. QOL includes the measurement of patient-reported outcomes, mostly described as the physical, social, emotional and functional wellbeing of the patient. These realms of wellbeing are reported by the patient themself and are thought to be a subjective measurement of response to treatment and/or treatment outcomes. Therapeutic interventions such as chemotherapy and/or radiation can thus be monitored from a patient perspective. In addition, while researchers and oncologists may recognize the futility of advanced and/or recurrent cancer therapy in the setting of reduced QOL, patients may have difficulty with discontinuing therapy. QOL research adds to the literature by introducing a patient perspective into the decision to treat aggressively. Specifically, in gynecologic cancers, there is a wide range of outcomes and patient characteristics to be considered. All three cancer settings - endometrial, cervical and ovarian - are remarkable in the QOL literature as this is a relatively new field with room to create interventions targeted towards improving QOL in often challenging clinical and life situations.